Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period - Deitcher, S R; Kessler, C M; Merli, G; Rigas, J R; Lyons, R M; Fareed, J (Clin Appl Thromb Hemost, 2006)
; ONCENOX Investigators.